Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparum have not been implemented because of the genetic and statistical complexity of the parasite mutations that confer resistance and their relation to treatment outcomes. This study analyzed pretreatment dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genotypes and treatment outcomes in a double-blind, placebo-controlled trial of sulfadoxine-pyrimethamine and chlorproguanildapsone treatment for uncomplicated P. falciparum malaria. Multiple logistic regression was used to identify mutations that were predictive of treatment failure and to identify interactions and confounding factors. Infections caused by parasites with 3 DHFR mutations and 2 DHPS mutations (the "quintuple mutant") were associated with sulfadoxine-pyrimethamine treatment failure but not with chlorproguanil-dapsone treatment failure. The presence of a single DHFR mutation (Arg-59) with a single DHPS mutation (Glu-540) accurately predicted the presence of the quintuple mutant. If this model is validated in other populations, it will finally be possible to use molecular markers for surveillance of antifolate-resistant P. falciparum malaria in Africa.
In response to evidence of high rates of chloroquine treatment failure, Malawi revised its national policy for treatment of malaria in 1993, becoming the first African country to adopt the antifolate combination sulfadoxine-pyrimethamine as its first-line antimalarial drug [1] . Several other eastern and southern African countries followed suit in recent years, and sulfadoxine-pyrimethamine is the second-line drug in most of the African countries in which chloroquine is still used.
The combination of the dihydrofolate reductase (DHFR) inhibitor chlorproguanil and the sulfone dapsone (LAPDAP, Glaxo SmithKline) is being considered as an alternative to or replacement for sulfadoxine-pyrimethamine in Africa, because it is effective in patients for whom sulfadoxine-pyrimethamine treatment has failed [2] , and, with its short half-life, it exerts less selective pressure for resistant parasites [3, 4] . Health officials charged with making therapy and prophylaxis policies are handicapped by a paucity of current and comprehensive data on resistance and by the limitations of available in vivo and in vitro methods of monitoring resistance [5] . Inexpensive reliable methods of measuring resistance are needed for monitoring the efficacy of sulfadoxine-pyrimethamine where it is already in use and for predicting its efficacy in areas where it is being considered as a replacement for chloroquine.
Mutations in the genes encoding the target enzymes of the antifolate drugs have been known for several years to be associated with in vitro resistance to these drugs. Mutations in DHFR confer resistance to pyrimethamine and the other DHFR inhibitors, and mutations in dihydropteroate synthase (DHPS) confer resistance to sulfadoxine and the other sulfas and sulfones. Rapid and inexpensive molecular assays for these mutations have been developed, and the many reported associations between these mutations and in vivo resistance have generated recommendations for use of molecular assays to monitor antifolate-resistant Plas-modium falciparum . However, none of the burgeoning number of molecular epidemiologic studies has provided specific recommendations that can be used to guide malaria treatment policies.
This lag between advances in our understanding of the genetics and epidemiology of drug resistance and practical application of molecular assays in ways that aid public health is mainly due to the complexity of the results of molecular surveys and the difficulty in relating them to treatment outcomes. With several mutations in 2 genes contributing to in vitro resistance to 2 drugs, it has been difficult to identify a specific set of mutations that predicts the treatment outcomes of antifolate combinations.
For DHFR, a point mutation causing a Ser!Asn change at position 108 confers pyrimethamine resistance in vitro with only a moderate loss of susceptibility to the DHFR inhibitors cycloguanil (the active metabolite of proguanil) and chlorcycloguanil (the active metabolite of chlorproguanil). The addition of the mutations Asn!Ile at codon 51 and/or Cys!Arg at codon 59 results in higher levels of pyrimethamine resistance, again with only modest effects on susceptibility to cycloguanil and chlorcycloguanil. A Ser!Thr mutation at position 108, coupled with an Ala!Val change at position 16, confers resistance to cycloguanil and chlorcycloguanil with only a moderate loss of susceptibility to pyrimethamine. Finally, an Ile!Leu change at position 164 (seen in Southeast Asia and South America in areas of high sulfadoxine-pyrimethamine resistance) combined with Asn-108 and Ile-51 and/or Arg-59 confers high-level resistance to both pyrimethamine and cycloguanil, with a more modest effect on susceptibility to chlorcycloguanil [29] [30] [31] [32] [33] . In some areas of South America, a Cys!Arg mutation at position 50 seems to have an effect similar to that of the Arg-59 mutation [15, 34] . In Africa, the DHFR triple mutant Asn-108/Ile-51/Arg-59 has been most strongly associated with resistance to sulfadoxine-pyrimethamine. The other DHFR mutations are extremely rare, or, in the case of the critical Leu-164 mutation, their presence in Africa has not yet been confirmed.
For DHPS, several point mutations are associated with in vitro resistance to sulfadoxine and the other sulfas and sulfones: Ser!Ala at codon 436, Ala!Gly at codon 437, Lys!Glu at codon 540, Ala!Gly at codon 581, and Ser!Phe at codon 436 coupled with either Ala!Thr or Ala!Ser at codon 613 [35, 36] . Among these, Gly-437, followed by Glu-540, is most strongly associated with sulfadoxine-pyrimethamine treatment failure in Africa [4, 15] .
The relative importance of mutations in DHFR and DHPS to sulfadoxine-pyrimethamine resistance in vivo has been debated [37, 38] . Parasites with fewer than the 3 DHFR mutations Asn-108, Ile-51, and Arg-59 may be cleared by sulfadoxinepyrimethamine, regardless of DHPS genotype [39] . In the presence of this DHFR triple mutant form, the DHPS genotype increases the likelihood of treatment failure. This model is consistent with field studies that show an association between the prevalence of mutations in both genes and sulfadoxine-pyrimethamine treatment failure rates and that demonstrate selection for mutations in both genes after sulfadoxine-pyrimethamine treatment [15, 17, 18, 40] . It is also consistent with a recent study that showed that patients infected with parasites carrying the DHPS double mutant Gly-437/Glu-540 and the DHFR triple mutant had a higher relative risk of treatment failure than did those infected with parasites carrying the DHFR triple mutant alone [4] .
The relationship between DHFR and DHPS mutations and antifolate resistance is less complicated in geographic areas in which the genetic complexity of P. falciparum is relatively low, where stable sets of DHFR and DHPS mutations are strongly associated with sulfadoxine-pyrimethamine resistance [17] . In most of sub-Saharan Africa, however, not only do DHFR and DHPS mutations occur in many different combinations, but most infections are polyclonal [26, 41, 42] , and, therefore, whether mutations on the 2 genes reside in the same parasites within a single infection cannot be determined. Such polyclonal infections also often are mixed at the loci of interest (i.e., individual infections carry some parasites with mutations at specific DHFR or DHPS codons and some parasites without mutations at those codons).
Because of the complicated nature of the molecular data generated by mutation-specific analysis, most field studies have been limited to reporting frequencies of mutations and, in some cases, describing associations between specific mutations or sets of mutations and different measures of treatment outcome. Univariate analyses have shown that the DHFR triple mutant Asn-108/Ile-51/ Arg-59, the DHPS double mutant Gly-437/Glu-540, and the DHFR and DHPS quintuple mutant carrying all 5 of these mutations are all statistically associated with sulfadoxine-pyrimethamine treatment failure in vivo [4] . However, multivariate analyses have not been done to determine which mutations or sets of mutations are independently associated with treatment failure and whether DHFR and DHPS mutations interact as risk factors for antifolate treatment failure.
That intrinsic parasite resistance is not the only factor determining treatment outcome is another obstacle to use of molecular assays for antifolate-resistant malaria. Infections caused by parasites with the same drug-resistance genotypes can have different treatment outcomes [4, 17] . This likely is related to host immunity, as is illustrated by the association between years of exposure to P. falciparum infection and the ability to clear chloroquine-resistant P. falciparum [43] . Other factors, such as subtherapeutic levels of drug, may also contribute to treatment outcomes.
To overcome these obstacles and move molecular assays for DHFR and DHPS into the realm of applied tools for surveillance, we analyzed DHFR and DHPS genotypes in relation to treatment outcomes in a randomized, double-blind trial of sulfadoxinepyrimethamine and chlorproguanil-dapsone efficacy in treating uncomplicated P. falciparum malaria in Malawian children. We designed a standardized system for interpreting polymerase chain reaction (PCR) results and used multivariate analysis to assess the role of specific sets of DHFR and DHPS mutations in sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment failure. We then sought to identify a subgroup of mutations that might serve as a simple but reliable marker to predict rates of sulfadoxine-pyrimethamine treatment failure.
Methods
Study site and design. Children aged 3 months to 6 years who presented with uncomplicated P. falciparum malaria to the Ndirande Health Centre in Blantyre, Malawi, were enrolled in a prospective, double-blind, placebo-controlled study comparing sulfadoxinepyrimethamine and chlorproguanil-dapsone. The clinical results of this trial will be reported elsewhere (J. Sulo, P. Chimpeni, J. Hatcher, J. G. Kublin , unpublished data). In brief, 500 children were randomly assigned to receive either a single dose of sulfadoxine-pyrimethamine and 2 daily doses of placebo or 3 daily doses of chlorproguanil-dapsone for each clinical malaria episode over the course of 1 year. Treatment outcomes were assessed by passive surveillance, in the form of continuous access to study clinicians for any illnesses, active surveillance by clinical and microscopic examination on posttreatment day 7, and monthly clinical evaluations for the duration of the study. For the purposes of this clinical trial, treatment outcomes were defined as follows: "sensitive," no illness accompanied by parasitemia on posttreatment days 3-6, no parasites detectable by microscopy at day 7, and no recurrence of parasitemia through day 28, and "treatment failure," parasitemia with or without illness on day 7. Treatment failures that occurred before day 7 were excluded, because many such early treatment failures in this setting are due to slow clearance of parasites without drug resistance (C.V.P., unpublished data); treatment failures that occurred after day 7 were excluded to avoid the difficulty of distinguishing reinfection from recrudescence in an area in which malaria transmission is ongoing.
Mutation analysis. Mutation-specific nested PCR and/or restriction digestions were used to analyze DHFR and DHPS mutations, as described elsewhere [5, 15, 26] . A detailed description of these methods is available at http://medschool.umaryland.edu/CVD/ plowe.html. In brief, parasite DNA was extracted from dried filterpaper blood samples and analyzed at DHFR codons 51, 59, 108, and 164 and at DHPS codons 437, 540, 581, and 613. Assays were not routinely done for mutations at DHFR codon 16, which are rare in field samples [19] , or at DHPS codon 436, because the Ala-436 mutation has not been associated with antifolate resistance in field studies [4, 15] and the Phe-436 mutation is rare in field samples [19] . To detect the presence of these rare mutations and to ascertain whether any new DHFR and DHPS mutations had emerged, 3 posttreatment samples from patients treated with sulfadoxine-pyramethamine and 3 from patients treated with chlorproguanil-dapsone were randomly chosen for DNA sequencing by the Biopolymer Laboratory, University of Maryland School of Medicine.
Codon analysis and interpretation. Codon analysis was done by investigators blinded to clinical outcomes. A novel system for characterizing and coding results of the molecular assays was designed to permit standardized analysis (figure 1). Each DHFR and DHPS codon was characterized as "wild type," "mixed" (both wildtype and mutant genotype clearly present in the same infection), or "pure" mutant (only mutant genotype detected). As illustrated in figure 1 , DHFR genotypes for each infection were then categorized as follows: "wild type," no mutations detected; "single," infections involving parasites with a single mutation (Asn-108); "double," infections involving some parasites with 2 mutations (Asn-108 and Ile-51 and/or Arg-59); "triple mixed," infections involving some parasites with all 3 mutations; and "triple pure," infections in which all 3 mutations were detected, at codons 108, 51, and 59, and with no evidence of any parasites with the wild-type sequence at these 3 codons. Similarly, DHPS genotypes were categorized as "wild type," no mutations detected; "single," infections involving some parasites with 1 of the DHPS mutations found in Malawi (Gly-437 or Glu-540); "double mixed," infections involving some parasites with both DHPS mutations; and "double pure," infections in which both of these mutations were detected and with no evidence of parasites with the wild-type sequence at these codons.
This system for coding molecular results was based on our confirmation that certain mutations occurred only in the presence of specific other mutations. Each infection was coded to designate the mini- Figure 1 . Codon analysis scheme for results of molecular assays for Plasmodium falciparum dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) mutations. As explained in detail in the section "Codon analysis and interpretation" in Methods, results for each infection were coded (e.g., "wild type," "single," or "double") based on the minimum number of mutations whose presence could be inferred on the basis of polymerase chain reaction results and on knowledge of which mutations occur only in the presence of other mutations. mum set of mutations that could be inferred to be present based on the results of PCR analysis of samples from the patient with that infection. For example, an infection involving parasites that yielded mixed results at DHFR codons 108, 51, and 59 would be coded as a "double mutant." Because mutations at codons 51 and 59 were only found in the presence of the codon 108 mutation, the presence of the 51 and 59 mutations indicates that some parasites involved in that infection carry at least 2 mutations. However, because it is possible that the infection included some parasites with mutations at codons 108 and 51 and other parasites with mutations at 108 and 59 but no parasites with mutations at all 3 codons, the definite presence of the DHFR triple mutant cannot be inferred. Similarly, an infection with mixed results at DHPS codons 437 and 540 was coded as "single mutant," because both of these mutations can occur independently, whereas an infection with only mutant results at codon 437 and mixed results at codon 540 was coded as a "DHPS mixed double mutant," because all parasites had the 437 mutation and some also had the 540 mutation. Finally, combined DHFR and DHPS genotypes were categorized as "single," "double," "triple," "quadruple," "quintuple mixed," or "quintuple pure," as shown in table 1. For example, DHFR and DHPS double mutant genotypes include parasites with DHFR double mutant and DHPS wild-type, DHFR single mutant and DHPS single mutant, and DHFR wild-type and DHPS double mutant genotypes.
To measure the association between DHFR and DHPS genotypes and treatment outcomes, the genotypes of parasites causing 49 clinical episodes that resulted in treatment failure were compared with those of the parasites causing 118 randomly selected infections that resulted in sensitive outcomes. Testing was done on samples obtained before treatment. The relationships between genotypes and outcomes were analyzed using a case-control design. All patients with day-7 treatment failures were included in the analysis as case patients and were compared with randomly selected control subjects with sensitive outcomes. The number of control subjects chosen was approximately twice the number of case patients, because statistical power in case-control studies improves significantly when the ratio of control subjects to case patients is increased from 1:1 to 2:1 [44] . To develop a simplified model for using molecular markers for surveillance of sulfadoxine-pyrimethamine resistance, we assessed the sensitivity and specificity of use of the presence of single and paired DHFR and DHPS mutations to predict the presence of the DHFR and DHPS pure quintuple mutant in 149 samples (among the 167 selected for analysis) for which all 5 codons of interest were successfully characterized. To determine the baseline prevalence in this population of the mutations most predictive of treatment failure, we measured the frequency of DHFR Ile-51 and Arg-59 and DHPS Glu-540 in pretreatment samples from 100 patients randomly selected from the whole study population without regard for treatment outcome.
Statistical analysis. We used x 2 tests to assess the significance of the association between mutations and resistance in the univariate analysis. Fisher's exact test was used to correct the x 2 tests when needed. Strength of association was evaluated using odds ratios (ORs). Multiple logistic regression models were fitted to assess the independent effects of the DHPS and DHFR mutations and to allow adjustment for hemoglobin levels. Likelihood ratio tests were used to evaluate the significance of each covariate in the model, and Wald tests were used to assess significance when covariates had .2 levels. The validity of mutations in 1 or 2 codons as predictors of quintuple mutations was assessed by calculation of sensitivity and specificity. Pure or mixed mutations and pure-only mutations were independently evaluated. Validity was considered to be optimal when the sum of sensitivity and specificity was maximized. All analyses were done using Stata 7.0 and S-Plus 4.5 (MathSoft) software. All confidence levels were set at 95%.
Results
We successfully analyzed 84 pretreatment samples of blood from patients with P. falciparum infections who were treated with sulfadoxine-pyrimethamine and 65 samples from patients who were treated with chlorproguanil-dapsone for DHFR mutations at all 3 of codons 108, 51, and 59 and DHPS mutations at codons 437 and 540. In the clinical study, the rate of failure for sulfadoxine-pyrimethamine treatment was higher (20.5%) than that for chlorproguanil-dapsone treatment (5.1%) (P , :01), and subjects were equally compliant with the sulfadoxine-pyrimethamine regimen and the chlorproguanil-dapsone regimen (Sulo et al., unpublished data). Fewer samples from patients treated with chlorproguanil-dapsone were analyzed, because the number of treatment failures in this group was low. Figure 2 shows that the majority of treatments succeeded when ,3 DHFR mutations, ,2 DHPS mutations, or ,5 mutations total were detected. Once these thresholds were exceeded, the majority of patients receiving sulfadoxine-pyrimethamine experienced treatment failure.
The DHFR triple mixed and triple pure mutant genotypes were associated with sulfadoxine-pyrimethamine treatment failure but not with chlorproguanil-dapsone treatment failure (figure 2 and figure 1 and combined to determine genotype for DHFR and DHPS.
a Mixed or pure.
Assays for Antifolate-Resistant P. falciparum JID 2002;185 (1 February)tables 2 and 3). The DHPS double mutant Gly-437/Glu-540, both in mixed and in pure form, was also associated with sulfadoxinepyrimethamine but not with chlorproguanil-dapsone treatment failure. The parasite genotype most highly mutated in both DHFR and DHPS in this setting has mutations in DHFR at codons 108, 51, and 59 and in DHPS at codons 437 and 540. This quintuple mutant, in either pure or mixed form, was the genotype most strongly associated with sulfadoxine-pyrimethamine treatment failure; the OR associated with this mutant was nearly twice that associated with the DHFR triple mutant in mixed or pure form and nearly 4 times that associated with the DHPS double mutant in mixed or pure form (table 2). The risk of treatment failure when the parasite causing the initial infection carried the quintuple mutant was markedly higher than the nonsignificant risk of failure when the parasite had the DHFR triple mutant alone (OR, 1.69; P ¼ :549) or the DHPS double mutant alone (OR, 0.41; P ¼ :449). A strong statistical interaction was observed between the DHFR triple mutant and the DHPS double mutant as risk factors for treatment failure (OR, 18.9; P ¼ :037). The quintuple mutant was not associated with chlorproguanil-dapsone treatment failure.
The role of factors other than DHFR and DHPS genotype in sulfadoxine-pyrimethamine treatment failure was assessed by adjusting the risk of treatment failure related to DHFR and DHPS mutations for hematocrit, age, and parasite density at the time of treatment. Lower hematocrit was significantly associated with risk of sulfadoxine-pyrimethamine treatment failure (table 4; multivariate adjusted OR, 4.0; P ¼ :04), but neither age nor parasite density at the time of infection was associated with treatment failure (data not shown).
Some infections appeared to be caused by parasites with genotypes of mixed form at codon 108 but mutant form at codons 51 and 59. Because direct DNA sequencing has not confirmed the existence of wild-type Ser-108 combined with mutant Ile-51 and/or Arg-59, it is likely that these results are the result of different PCR detection thresholds for the different mutations. No mutations at DHFR position 164 or DHPS position 581 or 613 were detected, and no new mutations were found in the samples that were sequenced.
We measured the sensitivity and specificity of the presence of each individual mutation as well as of all possible pairs of mutations for predicting the presence of the quintuple mutant among 149 infections analyzed at all 5 codons (table 5) . When present in either mixed or pure mutant form, all mutations and pairs of mutations were 100% sensitive as surrogate markers for the quintuple mutant, although specificities were poor. Specificities were markedly improved at a moderate cost to sensitivity by the use of pure mutant forms as predictors of the quintuple mutant. The combination of DHFR Arg-59 and DHPS Glu-540 in pure form was the most valid predictor of the quintuple mutant, with 92% sensitivity and 90% specificity (table 5) .
We randomly selected 100 pretreatment samples to measure the baseline prevalence of the DHFR and DHPS mutations in this study population. On the basis of their correlation with the presence of the quintuple mutant, the DHFR Ile-51/Arg-59 and the DHPS Glu-540 mutations were analyzed. In this randomly selected group of samples, the combination of DHFR Ile-51 and DHPS Glu-540 was present in 70% of the samples, of DHFR Arg-59 and DHPS Glu-540 in 65%, and of all 3 mutations in 64%. The DHFR triple mutant (indicated by the presence of DHFR Ile-51/Arg-59), at 78%, was more common than the quintuple mutant (indicated by the presence of DHFR Ile-51/Arg-59 and DHPS Glu-540), at 64%. Among the 50 samples from patients who were treated with sulfadoxine-pyrimethamine in this randomly selected subset, 30% were from patients who experienced treatment failure. 
Discussion
The presence of 3 mutations in DHFR and 2 mutations in DHPS in P. falciparum was strongly associated with failure of sulfadoxine-pyrimethamine but not chlorproguanil-dapsone treatment. Both the DHFR triple mutant Asn-108/Ile-51/Arg-59 and the DHPS double mutant Gly-437/Glu-540 were independently associated with sulfadoxine-pyrimethamine failure, and logistic regression showed that the 2 sets of mutations interact and that the presence of all 5 mutations (the quintuple mutant) was most strongly associated with treatment failure. These results are consistent with the idea that the DHFR triple mutant is necessary but not sufficient for sulfadoxine-pyrimethamine treatment failure but that DHPS mutations and possibly other factors determine whether treatment failure occurs in the presence of the triple mutant [39] . Although the DHFR triple mutant is strongly associated with sulfadoxine-pyrimethamine treatment failure, the quintuple mutant is less prevalent and more specific, making it a more suitable marker for treatment failure. Because DHFR and DHPS mutations occur in a stepwise manner, assays for carefully chosen single DHFR and DHPS mutations can predict the presence of the quintuple mutant. This would eliminate the need to perform assays for more than 2 mutations to assess levels of sulfadoxinepyrimethamine treatment failure. With a new, standardized system for classifying results of molecular assays, we now have a model that, if its use in other populations is validated, can be applied directly to surveillance of sulfadoxine-pyrimethamine treatment failure.
Our findings confirm that the P. falciparum mutations associated with sulfadoxine-pyrimethamine resistance in Africa do not impair the clinical efficacy of chlorproguanil-dapsone, a recently developed antifolate combination shortly to be subjected to regulatory review. Chlorproguanil-dapsone is likely to be introduced in areas where sulfadoxine-pyrimethamine resistance has reached unacceptable levels. The low rates of chlorproguanil-dapsone treatment failure in the face of a prevalence of the quintuple mutant of .60% supports the view that this antifolate combination will remain effective unless and until the DHFR mutation Leu-164 appears in Africa. This mutation is associated with highlevel resistance to the active metabolite of chlorproguanil in vitro and with high rates of sulfadoxine-pyrimethamine treatment failure in South America and Southeast Asia [15, 17, 34] . Continued surveillance for this mutation in Africa is warranted, particularly in areas with high rates of sulfadoxine-pyrimethamine treatment failure. It would also be prudent to continue surveillance for the Assays for Antifolate-Resistant P. falciparum JID 2002;185 (1 February) DHPS mutation at codon 581, which is associated with high rates of sulfadoxine-pyrimethamine resistance in South America and Southeast Asia but remains rare in Africa [15, 17] .
Where resources for molecular assays are limited, we recommend limiting surveillance for these rare mutations to periodic surveys at sentinel sites or where significant chlorproguanildapsone resistance is observed. Surveillance for other mutations that are rarely found in nature or do not appear to be associated with resistance in epidemiologic surveys, including DHFR Val-16 and Thr-108 and DHPS mutations at codons 436 and 613, can likewise be limited to settings in which there is a reason to suspect their presence. At sites that have the capability to do DNA sequencing, periodic sequencing of subsets of samples to monitor for the appearance of rare or new mutations is recommended.
How, then, should molecular assays be used for surveillance of antifolate-resistant P. falciparum and to inform treatment and prevention policy? We recommend that regional research centers in Africa, several of which already can perform these assays, start with surveys for all 5 of the DHFR and DHPS mutations commonly found in Africa. In this study, we found that DHFR Arg-59 and DHPS Glu-540 in pure form can be used to predict the presence of the quintuple mutant with a high degree of accuracy. Because the ability to distinguish mixed from pure infections can vary with different concentrations of template DNA and under different PCR conditions, and because the relative prevalence of these 2 mutations varies in different settings, the choice of surrogate markers for the quintuple mutant needs to be validated in other countries and laboratories. It then will be necessary to relate the prevalence of the molecular markers to the prevalence of treatment failure.
A model that uses a molecular marker for chloroquine resistance was recently described [45] . Dividing the prevalence of the marker (in the case of sulfadoxine-pyrimethamine resistance, DHFR Arg-59 accompanied by DHPS Glu-540 in pure form) by the prevalence of parasitologic resistance yields a genotype-resistance index (GRI). Similarly, a genotype-failure index (GFI) can be calculated to predict rates of therapeutic efficacy by using newer definitions recommended by the World Health Organization (WHO) [46] . These indices must be adjusted for age by logistic regression analysis before they will be comparable for studies done at different times and at sites with different rates of malaria transmission and host immunity [45] . Once established, these indices may permit prediction of rates of resistance to sulfadoxine-pyrimethamine and treatment failure, based on crosssectional surveys for just 2 mutations.
To permit this first evaluation of our model with a minimum of confounding, we used an unusual definition of treatment failure to allow the highest degree of confidence that treatment failures were due to drug resistance and not to slow parasite clearance or reinfection. To establish and validate GRIs and GFIs for sulfadoxine-pyrimethamine, it will be necessary to use standardized definitions of parasitologic resistance and treatment failure. Most in vivo malaria drug efficacy studies use variations of pro- tocols recommended by the WHO. These protocols have limitations, including overestimation of high-level parasitologic resistance and early treatment failure, and may need to be revised [47] . Universal application of these methods will require a harmonization of measures of drug treatment outcome. Nevertheless, by using the definition of treatment failure adopted for this study, a preliminary estimation of GFI can still be made: Among the 100 randomly selected samples that were assayed for DHFR and DHPS mutations, 50 were from patients who had been treated with sulfadoxine-pyrimethamine, and, in 30% of those, treatment failed. The GFI for DHFR Arg-59 and DHPS Glu-540 is the prevalence of this combination of mutations divided by the prevalence of failure, or 65% divided by 30%, yielding a GFI of 2.2. If similar GFIs are validated and are stable after age adjustment, they could be used to predict sulfadoxine treatment failure rates of approximately one-half of the prevalence of the DHFR Arg-59 and DHPS Glu-540 genotype in a given setting. This study confirms that mutations in P. falciparum DHPS and DHFR are important predictors of sulfadoxine-pyrimethamine resistance in Malawi, the first African country to adopt this drug combination as its front-line treatment against malaria. Further research on and discussion of the relative importance of these mutations to resistance and the exact mechanisms by which they exert their effect continue to be of scientific interest but will not speed the process of developing practical tools for monitoring antifolate resistance in endemic areas. We recommend multisite collaboration and use of harmonized clinical and molecular protocols to validate and refine the model proposed here. Techniques that offer practical advantages to in vivo studies and that can be applied meaningfully in the field will only become available if this type of simplified model for using molecular assays to conduct surveillance for drug-resistant P. falciparum can be validated and implemented.
